001     119829
005     20240228145441.0
024 7 _ |a 10.1021/acs.jmedchem.6b01111
|2 doi
024 7 _ |a pmid:28103033
|2 pmid
024 7 _ |a 0022-2623
|2 ISSN
024 7 _ |a 0095-9065
|2 ISSN
024 7 _ |a 1520-4804
|2 ISSN
024 7 _ |a 1943-2992
|2 ISSN
024 7 _ |a altmetric:16144769
|2 altmetric
037 _ _ |a DKFZ-2017-00424
041 _ _ |a eng
082 _ _ |a 540
100 1 _ |a Prescher, Horst
|0 http://orcid.org/0000-0002-4882-2252
|b 0
245 _ _ |a Design, Synthesis, and Biological Evaluation of Small, High-Affinity Siglec-7 Ligands: Toward Novel Inhibitors of Cancer Immune Evasion.
260 _ _ |a Washington, DC
|c 2017
|b ACS
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1521726899_2108
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Natural killer cells are able to directly lyse tumor cells, thereby participating in the immune surveillance against cancer. Unfortunately, many cancer cells use immune evasion strategies to avoid their eradication by the immune system. A prominent escape strategy of malignant cells is to camouflage themselves with Siglec-7 ligands, thereby recruiting the inhibitory receptor Siglec-7 expressed on the NK cell surface which subsequently inhibits NK-cell-mediated lysis. Here we describe the synthesis and evaluation of the first, high-affinity low molecular weight Siglec-7 ligands to interfere with cancer cell immune evasion. The compounds are Sialic acid derivatives and bind with low micromolar Kd values to Siglec-7. They display up to a 5000-fold enhanced affinity over the unmodified sialic acid scaffold αMe Neu5Ac, the smallest known natural Siglec-7 ligand. Our results provide a novel immuno-oncology strategy employing natural immunity in the fight against cancers, in particular blocking Siglec-7 with low molecular weight compounds.
536 _ _ |a 314 - Tumor immunology (POF3-314)
|0 G:(DE-HGF)POF3-314
|c POF3-314
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Frank, Martin
|0 P:(DE-HGF)0
|b 1
700 1 _ |a Gütgemann, Stephan
|b 2
700 1 _ |a Kuhfeldt, Elena
|b 3
700 1 _ |a Schweizer, Astrid
|b 4
700 1 _ |a Nitschke, Lars
|b 5
700 1 _ |a Watzl, Carsten
|b 6
700 1 _ |a Brossmer, Reinhard
|b 7
773 _ _ |a 10.1021/acs.jmedchem.6b01111
|g Vol. 60, no. 3, p. 941 - 956
|0 PERI:(DE-600)1491411-6
|n 3
|p 941 - 956
|t Journal of medicinal chemistry
|v 60
|y 2017
|x 1520-4804
909 C O |p VDB
|o oai:inrepo02.dkfz.de:119829
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-HGF)0
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-314
|2 G:(DE-HGF)POF3-300
|v Tumor immunology
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2017
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b J MED CHEM : 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b J MED CHEM : 2015
920 1 _ |0 I:(DE-He78)W160-20160331
|k W160
|l Molekulare Strukturanalyse
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)W160-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21